Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
Global stock market chart and trading board - stock photo
Representative image of stock market chart on a glowing particle world map and trading board. (Photo by Yuichiro Chino/Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Updated Jul 02, 2025 | 8:31 PM GMT-04
Share this article

Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson & Johnson (JNJ) announced that sales of the oncology drug Darzalex rose over 20% in the first quarter of 2025.

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.

Genmab licensed daratumumab to Johnson & Johnson unit Janssen Biotech, Inc. in August 2012.

Darzalex is a prescription medication used to treat multiple myeloma, a type of blood cancer. For the three months through the end of March, Johnson & Johnson reported sales of $3.24 billion for Darzalex, marking a growth of 20.3% year-on-year.

Darzalex accounted for over 23% of the company’s overall sales in its innovative medicine segment and nearly 15% of its overall reported sales.

Darzalex sales in the U.S. jumped 25% to $1.83 billion during the quarter, while sales outside the country jumped 15% to $1.41 billion.

The rise in Darzalex sales enabled the company to offset the 34% drop in sales of its immunology drug Stelara to $1.63 billion.

On Stocktwits, retail sentiment around Genmab fell marginally while staying within ‘extremely bullish’ territory over the past 24 hours, while message volume dropped to ‘extremely low’ levels.

GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits
GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits


A Stocktwits user opined that Genmab shares are cheap.

https://stocktwits.com/Pika_Capital/message/611668890

GMAB stock fell by about 7% year-to-date and over 33% over the past 12 months.

Also See: Dow Jones Futures Tick Higher As Investors Await Earnings, Monitor Tariff Developments

Subscribe to The Daily Rip
All Newsletters
Get the daily email that keeps you tuned in and makes markets fun again.

For updates and corrections, email newsroom[at]stocktwits[dot]com

Read about our editorial guidelines and ethics policy

Advertisement. Remove ads.